IN2014MN01575A - - Google Patents

Info

Publication number
IN2014MN01575A
IN2014MN01575A IN1575MUN2014A IN2014MN01575A IN 2014MN01575 A IN2014MN01575 A IN 2014MN01575A IN 1575MUN2014 A IN1575MUN2014 A IN 1575MUN2014A IN 2014MN01575 A IN2014MN01575 A IN 2014MN01575A
Authority
IN
India
Prior art keywords
methyl
pyrido
dimethylbutyl
pyrimidin
methylamino
Prior art date
Application number
Inventor
Matthew Carl Allgeier
Daniel L Flynn
Michael D Kaufman
Phenil J Patel
Craig D Wolfangel
Original Assignee
Lilly Co Eli
Deciphera Pharmaceuticals Llc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=47884613&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=IN2014MN01575(A) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Lilly Co Eli, Deciphera Pharmaceuticals Llc filed Critical Lilly Co Eli
Publication of IN2014MN01575A publication Critical patent/IN2014MN01575A/en

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D471/00Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04Ortho-condensed systems
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/4985Pyrazines or piperazines ortho- or peri-condensed with heterocyclic ring systems
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents
    • A61P35/02Antineoplastic agents specific for leukemia
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D471/00Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/12Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains three hetero rings

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Hematology (AREA)
  • Oncology (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Medicinal Preparation (AREA)

Abstract

The present invention provides the compound l (3 3 Dimethylbutyl) 3 (2 fluoro 4 methyl 5 (7 methyl 2 (methylamino)pyrido[2 3 d]pyrimidin 6 yl)phenyl)urea or a pharmaceutically acceptable salt thereof that inhibits Raf and therefore may be useful in treating cancer.
IN1575MUN2014 2012-03-07 2013-03-05 IN2014MN01575A (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201261607702P 2012-03-07 2012-03-07
PCT/US2013/029084 WO2013134243A1 (en) 2012-03-07 2013-03-05 2-amino, 6-phenyl substituted pyrido [2, 3 - d] pyrimidine derivatives useful as raf kinase inhibitors

Publications (1)

Publication Number Publication Date
IN2014MN01575A true IN2014MN01575A (en) 2015-05-08

Family

ID=47884613

Family Applications (1)

Application Number Title Priority Date Filing Date
IN1575MUN2014 IN2014MN01575A (en) 2012-03-07 2013-03-05

Country Status (39)

Country Link
US (2) US9334267B2 (en)
EP (1) EP2850082B1 (en)
JP (1) JP2015509536A (en)
KR (1) KR20140129087A (en)
CN (1) CN104302646B (en)
AP (1) AP2014007899A0 (en)
AR (1) AR090151A1 (en)
AU (1) AU2013230146B2 (en)
BR (1) BR112014018528A8 (en)
CA (1) CA2863673A1 (en)
CL (1) CL2014002220A1 (en)
CO (1) CO7010837A2 (en)
CR (1) CR20140378A (en)
CY (1) CY1117846T1 (en)
DK (1) DK2850082T3 (en)
DO (1) DOP2014000200A (en)
EA (1) EA024824B1 (en)
EC (1) ECSP14017584A (en)
ES (1) ES2584387T3 (en)
HK (1) HK1202541A1 (en)
HR (1) HRP20160654T1 (en)
HU (1) HUE028095T2 (en)
IL (1) IL234052A (en)
IN (1) IN2014MN01575A (en)
LT (1) LT2850082T (en)
MA (1) MA37316B1 (en)
ME (1) ME02423B (en)
MX (1) MX2014010701A (en)
NZ (1) NZ627454A (en)
PE (1) PE20142338A1 (en)
PH (1) PH12014501986A1 (en)
PT (1) PT2850082T (en)
RS (1) RS54840B1 (en)
SG (1) SG11201404969YA (en)
SI (1) SI2850082T1 (en)
TN (1) TN2014000375A1 (en)
TW (1) TW201348233A (en)
UA (1) UA112340C2 (en)
WO (2) WO2013134243A1 (en)

Families Citing this family (41)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AR090151A1 (en) * 2012-03-07 2014-10-22 Lilly Co Eli RAF INHIBITING COMPOUNDS
US8461179B1 (en) 2012-06-07 2013-06-11 Deciphera Pharmaceuticals, Llc Dihydronaphthyridines and related compounds useful as kinase inhibitors for the treatment of proliferative diseases
TWI704151B (en) 2014-12-22 2020-09-11 美商美國禮來大藥廠 Erk inhibitors
US20190175609A1 (en) * 2016-06-10 2019-06-13 Novartis Ag Therapeutic uses of a c-raf inhibitor
JP7219218B2 (en) 2016-12-22 2023-02-07 ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング Novel benzylamino-substituted quinazolines and derivatives as SOS1 inhibitors
AU2018258581A1 (en) * 2017-04-28 2019-11-07 Quartz Therapeutics, Inc. RAF-degrading conjugate compounds
AU2018390927B2 (en) 2017-12-21 2023-01-12 Boehringer Ingelheim International Gmbh Novel benzylamino substituted pyridopyrimidinones and derivatives as SOS1 inhibitors
JP7161849B2 (en) * 2018-01-24 2022-10-27 株式会社クラレ Method for producing primary amine
KR20200115607A (en) 2018-01-31 2020-10-07 데시페라 파마슈티칼스, 엘엘씨. Combination therapy for the treatment of gastrointestinal stromal tumors
EP3849536A4 (en) 2018-09-10 2022-06-29 Mirati Therapeutics, Inc. Combination therapies
SI3902547T1 (en) 2018-12-28 2024-02-29 Deciphera Pharmaceuticals, Llc Csf1r inhibitors for use in treating cancer
FI3921030T3 (en) 2019-02-06 2024-01-08 Lilly Co Eli 1-((2-(2,2,2-trifluoroethoxy)pyridin-4-yl)methyl)urea derivatives as kcnq potentiators
AR118826A1 (en) 2019-05-03 2021-11-03 Kinnate Biopharma Inc RAF KINASE INHIBITORS
WO2020231808A1 (en) 2019-05-10 2020-11-19 Deciphera Pharmaceuticals, Llc Heteroarylaminopyrimidine amide autophagy inhibitors and methods of use thereof
EP4342469A3 (en) 2019-05-10 2024-06-19 Deciphera Pharmaceuticals, LLC Phenylaminopyrimidine amide autophagy inhibitors and methods of use thereof
MX2021015628A (en) 2019-06-17 2022-04-18 Deciphera Pharmaceuticals Llc Aminopyrimidine amide autophagy inhibitors and methods of use thereof.
KR20220045189A (en) 2019-08-12 2022-04-12 데시페라 파마슈티칼스, 엘엘씨. How to treat gastrointestinal stromal tumors
WO2021030405A1 (en) 2019-08-12 2021-02-18 Deciphera Pharmaceuticals, Llc Ripretinib for treating gastrointestinal stromal tumors
IL293864A (en) 2019-12-30 2022-08-01 Deciphera Pharmaceuticals Llc Compositions of 1-(4-bromo-5-(1-ethyl-7-(methylamino)-2-oxo-1,2-dihydro-1,6-naphthyridin-3-yl)-2-fluorophenyl)-3-phenylurea
KR20220123057A (en) 2019-12-30 2022-09-05 데시페라 파마슈티칼스, 엘엘씨. Amorphous kinase inhibitor formulations and methods of use thereof
CN116234806A (en) 2020-06-02 2023-06-06 勃林格殷格翰国际有限公司 Cyclic 2-amino-3-cyanothiophenes and derivatives thereof for the treatment of cancer
US11407737B2 (en) 2020-09-18 2022-08-09 Kinnate Biopharma Inc. Inhibitors of RAF kinases
WO2022081469A1 (en) 2020-10-12 2022-04-21 Kinnate Biopharma Inc. Inhibitors of raf kinases
EP4237423A1 (en) 2020-11-02 2023-09-06 Boehringer Ingelheim International GmbH Substituted 1h-pyrazolo[4,3-c]pyridines and derivatives as egfr inhibitors
CA3198943A1 (en) 2020-11-18 2022-05-27 Daniel L. Flynn Gcn2 and perk kinase inhibitors and methods of use thereof
CA3203111A1 (en) 2020-12-22 2022-06-30 Kailiang Wang Sos1 inhibitors and uses thereof
WO2022226261A1 (en) 2021-04-23 2022-10-27 Kinnate Biopharma Inc. Treatment of cancer with a raf inhibitor
US20220388986A1 (en) 2021-04-29 2022-12-08 Boehringer Ingelheim International Gmbh Heterocyclic compounds capable of activating sting
WO2023099623A1 (en) 2021-12-01 2023-06-08 Boehringer Ingelheim International Gmbh Annulated 2-amino-3-cyano thiophenes and derivatives for the treatment of cancer
TW202340209A (en) 2021-12-01 2023-10-16 德商百靈佳殷格翰國際股份有限公司 Annulated 2-amino-3-cyano thiophenes and derivatives for the treatment of cancer
WO2023099592A1 (en) 2021-12-01 2023-06-08 Boehringer Ingelheim International Gmbh Annulated 2-amino-3-cyano thiophenes and derivatives for the treatment of cancer
TW202337432A (en) 2021-12-01 2023-10-01 德商百靈佳殷格翰國際股份有限公司 Annulated 2-amino-3-cyano thiophenes and derivatives for the treatment of cancer
WO2023099624A1 (en) 2021-12-01 2023-06-08 Boehringer Ingelheim International Gmbh Annulated 2-amino-3-cyano thiophenes and derivatives for the treatment of cancer
WO2023099620A1 (en) 2021-12-01 2023-06-08 Boehringer Ingelheim International Gmbh Kras degrading compounds comprising annulated 2-amino-3-cyano thiophenes
CA3240192A1 (en) 2021-12-09 2023-06-15 Daniel L. Flynn Raf kinase inhibitors and methods of use thereof
WO2023118250A1 (en) 2021-12-23 2023-06-29 Boehringer Ingelheim International Gmbh 8-aza quinazolines as brain-penetrant sos1-inhibitors
WO2023173017A1 (en) * 2022-03-09 2023-09-14 Blossomhill Therapeutics, Inc. Kras inhibitors for treating disease
US11779572B1 (en) 2022-09-02 2023-10-10 Deciphera Pharmaceuticals, Llc Methods of treating gastrointestinal stromal tumors
WO2024088991A1 (en) 2022-10-26 2024-05-02 Boehringer Ingelheim International Gmbh Heterocyclic compounds capable of activating sting
WO2024089008A1 (en) 2022-10-26 2024-05-02 Boehringer Ingelheim International Gmbh Heterocyclic compounds capable of activating sting
US20240174641A1 (en) 2022-10-26 2024-05-30 Boehringer Ingelheim International Gmbh Heterocyclic compounds capable of activating sting

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2003033472A1 (en) * 2001-10-17 2003-04-24 Kirin Beer Kabushiki Kaisha Quinoline or quinazoline derivatives inhibiting auto- phosphorylation of fibroblast growth factor receptors
AU2003280599A1 (en) * 2002-10-29 2004-05-25 Kirin Beer Kabushiki Kaisha QUINOLINE DERIVATIVES AND QUINAZOLINE DERIVATIVES INHIBITING AUTOPHOSPHORYLATION OF Flt3 AND MEDICINAL COMPOSITIONS CONTAINING THE SAME
US20070054916A1 (en) 2004-10-01 2007-03-08 Amgen Inc. Aryl nitrogen-containing bicyclic compounds and methods of use
US8188113B2 (en) * 2006-09-14 2012-05-29 Deciphera Pharmaceuticals, Inc. Dihydropyridopyrimidinyl, dihydronaphthyidinyl and related compounds useful as kinase inhibitors for the treatment of proliferative diseases
US7897762B2 (en) 2006-09-14 2011-03-01 Deciphera Pharmaceuticals, Llc Kinase inhibitors useful for the treatment of proliferative diseases
TW201139436A (en) 2010-02-09 2011-11-16 Exelixis Inc Methods of treating cancer using pyridopyrimidinone inhibitors of PI3K and mTOR in combination with autophagy inhibitors
AR090151A1 (en) * 2012-03-07 2014-10-22 Lilly Co Eli RAF INHIBITING COMPOUNDS

Also Published As

Publication number Publication date
IL234052A (en) 2016-05-31
AR090151A1 (en) 2014-10-22
US9334267B2 (en) 2016-05-10
PH12014501986B1 (en) 2014-11-24
RS54840B1 (en) 2016-10-31
EP2850082A1 (en) 2015-03-25
PH12014501986A1 (en) 2014-11-24
CN104302646B (en) 2016-05-04
BR112014018528A8 (en) 2017-07-11
ME02423B (en) 2016-09-20
CL2014002220A1 (en) 2015-06-05
HK1202541A1 (en) 2015-10-02
CN104302646A (en) 2015-01-21
TN2014000375A1 (en) 2015-12-21
EA201491456A1 (en) 2014-12-30
AP2014007899A0 (en) 2014-08-31
US20130252977A1 (en) 2013-09-26
HUE028095T2 (en) 2016-11-28
US20150119392A1 (en) 2015-04-30
US8741911B2 (en) 2014-06-03
DK2850082T3 (en) 2016-08-15
UA112340C2 (en) 2016-08-25
WO2013134243A1 (en) 2013-09-12
PT2850082T (en) 2016-07-15
CA2863673A1 (en) 2013-09-12
BR112014018528A2 (en) 2017-06-20
LT2850082T (en) 2016-09-12
PE20142338A1 (en) 2015-01-10
JP2015509536A (en) 2015-03-30
ES2584387T3 (en) 2016-09-27
MX2014010701A (en) 2015-03-10
EA024824B1 (en) 2016-10-31
KR20140129087A (en) 2014-11-06
MA37316B1 (en) 2017-03-31
SI2850082T1 (en) 2016-07-29
CY1117846T1 (en) 2017-05-17
AU2013230146A1 (en) 2014-08-14
WO2013134252A1 (en) 2013-09-12
ECSP14017584A (en) 2016-01-29
AU2013230146B2 (en) 2015-09-10
DOP2014000200A (en) 2014-10-15
CO7010837A2 (en) 2014-07-31
HRP20160654T1 (en) 2016-07-01
CR20140378A (en) 2014-11-27
MA37316A1 (en) 2016-06-30
EP2850082B1 (en) 2016-05-18
TW201348233A (en) 2013-12-01
SG11201404969YA (en) 2014-10-30
NZ627454A (en) 2016-09-30

Similar Documents

Publication Publication Date Title
IN2014MN01575A (en)
IL228968A0 (en) Kinase inhibitors pyrazolo [4,3-d]pyrimidine compounds,compositions comprising the same and uses thereof
ZA201506570B (en) 2-phenylimidazo[1,2-a]pyrimidines as imaging agents
IL246028A0 (en) 2-amino-6-fluoro-n-[5-fluoro-pyridin-3-yl]pyrazolo[1,5-a]pyrimidin-3-carboxamide compounds, solid forms comprising same, compositions comprising same and processes for producing same
ZA201802181B (en) 2¿phenyl¿3,4¿dihydropyrrolo[2,1 ¿f] [1,2,4]triazinone derivatives as phosphodiesterase inhibitors and uses thereof
IL229606A0 (en) Pyrazolo [3,4-d] pyrimidine compounds and their use as pde2 inhibitors and/or cyp3a4 inhibitors
SI2914594T1 (en) Amino-substituted imidazo(1,2-a)pyridinecarboxamides and their use
HK1187606A1 (en) Substituted 6,6-fused nitrogenous heterocyclic compounds and uses thereof 66-
MX2016006432A (en) Tetrahydro-benzodiazepinones.
EP2857403A4 (en) Pyrrolo[2,1-f][1,2,4]triazine compound, and preparation method and application thereof
HK1193100A1 (en) Phenyl-3-aza-bicyclo[3.1.0]hex-3-yl-methanones and the use thereof as medicament -3--[310]-3--
PL2634174T3 (en) Nitrogen-containing heterocyclic derivate having 2-imino group and pest control agent including the same
PL2833490T3 (en) Electrified rail, particularly for powering metal shelving units, and method for its manufacturing
MX2015000362A (en) Antiproliferative benzo [b] azepin- 2 - ones.
IL262673A (en) Pyrazolo[1,5-a]pyrimidine compound
IL235949A (en) Pyrrolo [2,1-f][1,2,4]triazine derivative and use thereof for treating tumors
IL224029A (en) Triazines and pyrimidines , compositions comprising same and use thereof for the treatment of insects
WO2015015301A3 (en) Cancer therapy with silver nanoparticles
SG11201809760TA (en) Novel 2,4,6-trisubstituted s-triazine compound, preparation method therefor, and use thereof
UY35034A (en) PROCESS FOR THE PREPARATION OF 2-AMINO-5,8-DIMETOXI [1,2,4] TRIAZOL [1,5-c] PYRIMIDINE FROM 4-CHLORINE-2,5-DIMETOXIPIRIMIDINE
CA141929S (en) Retainer for railings
EP2976342A4 (en) 2-substituted imidazo[4,5-d]phenanthroline derivatives and their use in the treatment of cancer
IL253427B (en) Pyrazolo[3,4-d]pyrimidin derivative and its use for the treatment of leishmaniasis
CL2014001265A1 (en) Compounds derived from uracil, axl and c-met kinase inhibitors, useful in the treatment of cancer.
CA142240S (en) Door stop